Skip to main content

Table 5 Pairwise comparison of the recommendations from the index MDT versus ESMO and NCCN guidelines

From: Computational prediction of multidisciplinary team decision-making for adjuvant breast cancer drug therapies: a machine learning approach

Treatment Modality Agreement between the expertise
Strategy MDT versus ESMO MDT versus NCCN ESMO versus NCCN
  N (%) N (%) N (%)
Chemotherapy
 Overalla 551/975 (57) 462/975 (47) 320/1065 (30)
 Aggressive 628/975 (64) 616/975 (63) 416/1065 (39)
 Conservative 729/975 (75) 731/975 (75) 721/1065 (68)
Endocrine therapy
 Overalla 853/1002 (85) 840/1002 (84) 976/1065 (92)
 Aggressive 970/1002 (97) 953/1002 (95) 1024/1065 (96)
 Conservative 858/1002 (86) 861/1002 (86) 976/1065 (92)
Trastuzumab
 Overalla 437/456 (96) 437/456 (96) 1047/1065 (98)
 Aggressive 444/456 (97) 446/456 (98) 1058/1065 (99)
 Conservative 437/456 (98) 440/456 (97) 1047/1065 (98)
  1. Abbreviations: MDT multidisciplinary team meeting, ESMO European Society for Medical Oncology guideline, NCCN National Comprehensive Cancer Network guideline
  2. aOverall – three-way grouping of “Recommended”, “For discussion”, “Not recommended”